Humanin dosage: why there is no validated human dose

A dosage page usually exists to tell you how much of something to take. This one exists to explain why that question cannot be answered honestly for humanin — because the number does not exist. Humanin is a genuine, well-studied mitochondrial-derived peptide, but it has been administered as a treatment only to cells in a dish and to laboratory animals. No human dosing trial has ever been run. For the underlying biology and why it draws longevity interest, start with the humanin evidence monograph; this page is strictly about the dosing question, and the answer is more candid than convenient.

There is no validated human dose

The simplest accurate statement is the most important one: no regulator, trial, or guideline has ever defined a human dose of humanin. There is no approved product, no pharmaceutical label, no titration schedule, and no published randomized study that gave humanin to people and reported a dose tied to a clinical outcome. Everything written below about “doses” describes what researchers used in experimental systems — figures that belong to mice and cell cultures, not to a protocol for a human being. Treating any of them as a personal dose is an extrapolation the science does not support.

The doses that exist live in cells and animals

Humanin entered the literature in 2001 as a factor that rescued neurons from death in culture, where its protective effect was characterized at micromolar concentrations in the dish — a concentration in a well, not a dose given to an organism.^[1] The animal work that followed administered the peptide by routes no one would self-manage: rodent experiments typically deliver humanin by intraperitoneal injection or directly into the brain, dosed per kilogram of body weight or as micrograms per animal, often on schedules designed around an experimental endpoint rather than chronic use. Even the landmark cognitive-aging study that paired mouse data with a human association dosed the mice — the human side of that paper measured naturally circulating humanin, it did not inject anyone.^[2] An intraperitoneal milligram-per-kilogram dose in a mouse is not a recipe you can scale to a person, and presenting it as one is exactly the move this page is here to flag.

Most of the data is really about HNG, not humanin

There is a deeper reason the animal doses do not transfer: a large share of the strongest preclinical results were obtained with an engineered analog, HNG (S14G-humanin), not with the native peptide at all. Substituting glycine at position 14 produces a far more potent and stable rescue factor than the molecule humanin itself, which is why labs reach for it.^[3] So a “humanin dose” quoted from a study is frequently an HNG dose, calibrated to a molecule that behaves differently and was never the thing in the vial. A product labelled “humanin” is not HNG, and borrowing HNG's experimental potency to justify a native-peptide dose double-counts a difference the researchers were careful to make.

In humans, humanin is measured — not dosed

Where humanin has been studied in people, it appears as a biomarker: a molecule researchers measure in blood, not one they administer. Circulating humanin tends to decline with age, and higher endogenous levels have been associated with markers of better cognitive aging in human cohorts.^[2] Animal work has likewise framed it as a regulator of lifespan and healthspan when its levels are manipulated internally.^[4] That is a meaningful research signal — but it describes the body's own peptide as an index of aging, not an injectable with a known effective dose. A biomarker that falls as you get older tells you something is changing; it does not come with instructions for how much to inject, and the human literature contains none.

What the marketed “protocols” actually are

Vendors nonetheless publish humanin injection protocols — specific microgram amounts, frequencies, and cycles presented with the confidence of a drug label. None of it is validated. These figures are not traceable to any human trial, because none exists; at best they are reverse-engineered from animal papers (often HNG papers), and at worst invented. Layered on top is the supply problem common to the unregulated peptide market: the product arrives from sources operating outside pharmaceutical manufacturing standards, so the identity, true quantity, purity, and sterility of what is in the vial are unverified — and a vial sold as “humanin” may not match the more-studied analog or even contain what the label claims. The same mechanism-outruns-evidence pattern shadows epitalon dosing and the broader NAD+ precursor field.

The honest bottom line

Reduced to what the evidence supports: there is no human dose of humanin. The biology is real and the preclinical work is genuine, but every dosing figure belongs to a cell culture or a laboratory animal — frequently to the engineered HNG analog rather than the native peptide — and none of it has been translated into a tested, safe human protocol.^[3][5] In people, humanin is something you measure as it declines with age, not something the literature tells you how to administer.^[2] Reviews of the mitochondrial-derived peptide field, written by the people building it, are explicit that therapeutic use remains preclinical.^[5] Any “dose” you encounter for sale is an unvalidated number attached to an unregulated product — a guess dressed as a protocol. For the full picture of what humanin does and does not show, return to the evidence monograph.